IS8529A - Rífamísínhliðstæður og notkun þeirra - Google Patents

Rífamísínhliðstæður og notkun þeirra

Info

Publication number
IS8529A
IS8529A IS8529A IS8529A IS8529A IS 8529 A IS8529 A IS 8529A IS 8529 A IS8529 A IS 8529A IS 8529 A IS8529 A IS 8529A IS 8529 A IS8529 A IS 8529A
Authority
IS
Iceland
Prior art keywords
rifamycin
analogues
rifamycin analogues
Prior art date
Application number
IS8529A
Other languages
English (en)
Inventor
Duzer John H Van
Arthur F Michaelis
William B Geiss
Douglas G Stafford
Raker Joseph
Xiang Y Yu
James M Siedlecki
Yang Yingfei
Original Assignee
Activbiotics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Activbiotics Inc filed Critical Activbiotics Inc
Publication of IS8529A publication Critical patent/IS8529A/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS8529A 2003-12-23 2006-07-14 Rífamísínhliðstæður og notkun þeirra IS8529A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53223703P 2003-12-23 2003-12-23
PCT/US2004/043093 WO2005062882A2 (en) 2003-12-23 2004-12-21 Rifamycin analogs and uses thereof

Publications (1)

Publication Number Publication Date
IS8529A true IS8529A (is) 2006-07-14

Family

ID=34738771

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8529A IS8529A (is) 2003-12-23 2006-07-14 Rífamísínhliðstæður og notkun þeirra

Country Status (11)

Country Link
US (2) US7271165B2 (is)
EP (1) EP1701962A4 (is)
JP (1) JP2007516291A (is)
KR (1) KR20070006698A (is)
CN (1) CN1918172B (is)
AR (1) AR047352A1 (is)
AU (1) AU2004308399A1 (is)
CA (1) CA2550729A1 (is)
IS (1) IS8529A (is)
TW (1) TW200533340A (is)
WO (1) WO2005062882A2 (is)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2536378A1 (en) 2003-08-22 2005-03-10 Activbiotics, Inc. Rifamycin analogs and uses thereof
WO2005058231A2 (en) 2003-12-10 2005-06-30 Activbiotics, Inc. Rifamycin analogs and uses thereof
WO2005062882A2 (en) * 2003-12-23 2005-07-14 Activbiotics, Inc Rifamycin analogs and uses thereof
EA016059B1 (ru) 2005-08-11 2012-01-30 Тарганта Терапьютикс Инк. Фосфонированные рифамицины и их применение для профилактики и лечения костных и суставных инфекций
MX2008007808A (es) * 2005-12-14 2008-09-15 Activbiotics Pharma Llc Analogos de rifamicina y usos de ellos.
TW200808723A (en) * 2006-03-13 2008-02-16 Univ California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
EA017564B1 (ru) * 2007-09-12 2013-01-30 Тарганта Терапьютикс Корп. Способ ингибирования клостридиум диффициле введением оритаванцина
WO2010019511A2 (en) 2008-08-13 2010-02-18 Targanta Therapeutics Corp. Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
WO2010067072A1 (en) 2008-12-10 2010-06-17 Cipla Limited Rifaximin complexes
ES2659763T3 (es) 2011-02-14 2018-03-19 The Regents Of The University Of Michigan Composiciones y procedimientos para el tratamiento de obesidad y trastornos relacionados
CA2833411C (en) * 2011-04-18 2019-06-18 Commonweath Scientific And Industrial Research Organisation Gas capture process
WO2013086415A1 (en) * 2011-12-09 2013-06-13 The Regents Of The University Of Michigan Antimicrobial compounds
CN102846580A (zh) * 2012-10-17 2013-01-02 岳池县神龙科技研发有限公司 利福平胶囊在制备治疗痔疮药物中的用途
ES2727898T3 (es) 2013-05-02 2019-10-21 Univ Michigan Regents Amlexanox deuterado con estabilidad metabólica mejorada
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
WO2014193722A1 (en) 2013-05-31 2014-12-04 Genentech, Inc. Anti-wall teichoic antibodies and conjugates
SI3004162T1 (sl) 2013-05-31 2020-07-31 Genentech, Inc. Protitelesa in konjugati, ki so usmerjeni proti celični steni bakterij, v kateri je teihoična kislina
RU2017118792A (ru) 2014-12-03 2019-01-09 Дженентек, Инк. Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение
RU2731055C2 (ru) 2014-12-03 2020-08-28 Дженентек, Инк. Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение
PL236355B1 (pl) 2015-04-02 2021-01-11 Celon Pharma Spolka Akcyjna Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
EP3407974A4 (en) 2016-01-29 2019-08-28 The Regents Of The University Of Michigan ANALOGUES OF AMLEXANOX
CA3012046C (en) 2016-03-04 2020-11-10 Genentech, Inc. Process for the preparation of an antibody-rifamycin conjugate
CN108794507B (zh) * 2017-04-26 2020-12-25 北京维德维康生物技术有限公司 一种利福昔明半抗原、人工抗原及其制备方法与应用
CN108003177B (zh) * 2017-12-21 2020-04-14 中国医药集团总公司四川抗菌素工业研究所 一种苯并噁嗪利福霉素类衍生物及其制备方法和用途
CN108047249A (zh) * 2017-12-21 2018-05-18 中国医药集团总公司四川抗菌素工业研究所 一种新型利福霉素衍生物及其制备方法和用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130099C (is) 1963-10-11
JPS58225093A (ja) 1982-06-25 1983-12-27 Kanegafuchi Chem Ind Co Ltd ベンゾチアジノリフアマイシン誘導体およびその製造法
JPS59231092A (ja) 1983-06-11 1984-12-25 Kanebo Ltd フエノチアジン型リフアマイシンおよびその医薬用途
US4690919A (en) 1984-01-04 1987-09-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Benzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
JPS6122090A (ja) 1984-07-09 1986-01-30 Kanebo Ltd アミノ置換フエノチアジン型リフアマイシンおよびその医薬用途
JPS62240688A (ja) 1986-04-12 1987-10-21 Kanegafuchi Chem Ind Co Ltd ヒドロキシメチル基を有するアミノベンゾキサジノおよびアミノベンゾチアジノリフアマイシン誘導体
JPS62242687A (ja) 1986-04-15 1987-10-23 Kanegafuchi Chem Ind Co Ltd 置換ベンゾキサジノおよび置換ベンゾチアジノリフアマイシン誘導体
JP2544375B2 (ja) 1986-07-14 1996-10-16 鐘淵化学工業株式会社 アルキル置換ベンゾキサジノリフアマイシン誘導体
JPS6335578A (ja) 1986-07-31 1988-02-16 Kanegafuchi Chem Ind Co Ltd ベンゾキサジノまたはベンゾチアジノリフアマイシン誘導体
JPS6335579A (ja) 1986-07-31 1988-02-16 Kanegafuchi Chem Ind Co Ltd 含硫ベンゾキサジノリフアマイシン誘導体
JPS63233987A (ja) 1987-03-23 1988-09-29 Kanegafuchi Chem Ind Co Ltd 4′−tert−ブチルベンゾキサジノリフアマイシン誘導体
ES2088870T3 (es) 1988-03-18 1996-10-01 Kanegafuchi Chemical Ind Un derivado de benzoxazinorrifamicina sustituida, un procedimiento para preparar el mismo y un agente antibacteriano que contiene el mismo.
CA1304363C (en) 1988-11-01 1992-06-30 Takehiko Yamane 3'-hydroxybenzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same
EP0616841B1 (en) 1992-10-09 1998-12-23 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Production method for fine granulate
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
ES2218597T3 (es) * 1995-09-01 2004-11-16 Kaneka Corporation Uso de derivados de rifamicina para la fabricacion de un medicamento para el tratamiento de enfermedades causadas por infecciones de helicobacter pylori.
US5981522A (en) 1995-09-01 1999-11-09 Kaneka Corporation Treatment of disease caused by infection of Helicobacter
JP3963976B2 (ja) * 1995-12-08 2007-08-22 株式会社カネカ クラミジア感染症治療剤
DE69829905T2 (de) * 1997-02-28 2006-03-09 Kaneka Corp. Heilmittel für durch Helicobacter verursachte Krankheit
US6486161B1 (en) 1998-07-29 2002-11-26 Kaneka Corporation Use of rifamycin derivative for treating mastitis in a domestic animal
US6316433B1 (en) 1998-12-18 2001-11-13 Kaneka Corporation Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
EP1511753A4 (en) 2001-09-06 2005-10-12 Activbiotics Inc ANTIMICROBIAL MEDIUM AND ITS USE
EP1453837A4 (en) 2001-11-21 2007-11-07 Activbiotics Inc TARGETED THERAPEUTIC AGENTS AND USES THEREOF
WO2003051300A2 (en) 2001-12-13 2003-06-26 Activbiotics, Inc. Metal complexes and formulations of rifamycin analogues and uses therof
AU2002364162A1 (en) 2001-12-13 2003-06-30 Activbiotics, Inc. Sulfhydryl rifamycins and uses thereof
US20040077533A1 (en) 2002-05-23 2004-04-22 Sayada Chalom B. Methods and compositions for treating bacterial infections and diseases associated therewith
EP1531828A4 (en) 2002-05-23 2005-11-02 Activbiotics Inc METHODS OF TREATING BACTERIAL INFECTIONS AND ASSOCIATED DISEASES
AU2003239919A1 (en) 2002-06-03 2003-12-19 Activbiotics, Inc. Intravenous rifalazil formulation and methods of use thereof
AU2003268330A1 (en) 2002-08-29 2004-03-19 Activbiotics, Inc. Methods and reagents for treating infections of clostridium difficile and diseases associated therewith
CA2536378A1 (en) * 2003-08-22 2005-03-10 Activbiotics, Inc. Rifamycin analogs and uses thereof
WO2005058231A2 (en) 2003-12-10 2005-06-30 Activbiotics, Inc. Rifamycin analogs and uses thereof
WO2005062882A2 (en) * 2003-12-23 2005-07-14 Activbiotics, Inc Rifamycin analogs and uses thereof

Also Published As

Publication number Publication date
CA2550729A1 (en) 2005-07-14
EP1701962A4 (en) 2008-03-05
US7271165B2 (en) 2007-09-18
CN1918172A (zh) 2007-02-21
CN1918172B (zh) 2011-09-14
WO2005062882A3 (en) 2005-12-29
EP1701962A2 (en) 2006-09-20
JP2007516291A (ja) 2007-06-21
KR20070006698A (ko) 2007-01-11
TW200533340A (en) 2005-10-16
US20050197333A1 (en) 2005-09-08
WO2005062882A2 (en) 2005-07-14
AR047352A1 (es) 2006-01-18
AU2004308399A1 (en) 2005-07-14
US20100273765A1 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
IS8529A (is) Rífamísínhliðstæður og notkun þeirra
NO20053974D0 (no) Tienopyrimidinforbindelser og anvendelse derav.
DK1711207T3 (da) Interferon-alpha-antistoffer og anvendelse heraf
NO20052524D0 (no) Aminerte isofiavonoidderivater og anvendelse derav
IS8153A (is) Ónæmisbælandi efnasambönd og efnablöndur
DE502004009865D1 (de) Ür knochen
NO20054095D0 (no) Pyridyloksymetyl og benzioksazolazabicyklisk derivater
DE60326145D1 (de) Spielermittlungsverfahren
IS8575A (is) 3-ß-D-ríbófúranósýlþíasóló [4,5-d]pýridímínnúkleósíð og notkun þeirra
IS8036A (is) Nýir sambræddir heteróhringir og notkun þeirra
ATE379983T1 (de) Klettverschluss
ATE512148T1 (de) Pyrazolo- und imidazopyrimidinderivate
DK1675852T3 (da) Heterocykliske 7-amino-alkylidenyl-quinoloner og -naphthyridoner
DK1840121T3 (da) Glycinderivat og anvendelse heraf
DE602004003111D1 (de) Tiefen-basiertes Antialiasing
DK1601744T3 (da) Forgasningsapparat og fremgangsmåde
DE502004002225D1 (de) Selbstemulgierende Zubereitungen
IS7783A (is) Flóð og fjöru-ker
IS8489A (is) Umritunarstillar og aðferðir þeirra
DK1562918T3 (da) Substituerede benzoxazinoner og anvendelser deraf
NO20052356D0 (no) Redningsskoyte
DK1662867T3 (da) Insekticid-forbindelser og fremgangsmåder til valg deraf
GB0318546D0 (en) Quinoxalinones and their use
NO20053898D0 (no) Use and proceeding at footballshoes
NO20032673D0 (no) Ereksjonshjelpemiddel